Akynzeo (Netupitant/Palonosetron HCl) Patent Expiration, LOE Window & CMS Spending
Akynzeo (Netupitant/Palonosetron HCl) by Helsinn Healthcare Sa: FDA Orange Book core substance LOE 2035-09-25, 0 AB generics, $444K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Helsinn Healthcare Sa |
| FDA Application & Pathway | N205718 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2035-09-25 |
| Last Listed Patent or Exclusivity Date | 2035-09-25 |
| Orange Book Patents (*PED Extensions) | 12 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $444K |
| 2024 Medicare Part D Spend | $354K |
| 2024 Medicaid Spend | $90K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |